Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

CTSO - Cytosorbents Corporation Последние новости | Finranks

Home

/

CTSO

C

Cytosorbents Corporation (CTSO)

NCM – Цена в реальном времени. Валюта: USD

0.38

+0.02 (5.83%)

Рынок открыт: Aug 12, 2026, 1:50 PM EDT

0.38

+0.02 (4.33%)

Предыдущая сессия: Aug 11, 2026, 6:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., Aug. 6, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update.

Видео

No Data

There is no data to display

Пресс-релизы

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., Aug. 6, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update.